Dr. Callahan is knowledgeable, dedicated, and explains clearly. She answered all my questions with patience. Her staff is pleasant, helpful, and always kind when I called with concerns.
Debbie Baker
Fluorescein Angiography for Age-Related Macular Degeneration
Why This Test Matters in AMD
Age-related macular degeneration affects the macula, the central part of the retina responsible for sharp, detailed vision. Fluorescein angiography plays a specific and important role in identifying which form of AMD is present and how best to respond to it.
AMD exists in two main forms. Dry AMD involves the gradual breakdown of light-sensitive cells in the macula and tends to progress slowly. Wet AMD occurs when abnormal new blood vessels grow beneath the retina, where they leak fluid or blood and can cause rapid, significant vision loss.
Fluorescein angiography is the most reliable test for confirming wet AMD and classifying the type of abnormal blood vessel growth present. This distinction directly determines whether treatment is needed and how urgently it should begin.
Choroidal neovascularization (CNV) is the medical term for abnormal new blood vessel growth from the choroid into or beneath the retina. It is the defining feature of wet AMD and the primary cause of severe vision loss in this condition.
On a fluorescein angiogram, CNV appears as an area of hyperfluorescence, meaning it glows brightly and that brightness expands in both size and intensity as the test progresses. This expanding pattern is distinct from other causes of brightness in the images and is a key sign your retina specialist uses to confirm active CNV.
The specific angiographic pattern of CNV helps a retina specialist determine how to approach treatment. The images reveal whether abnormal vessels are located directly beneath the center of vision or off to the side, along with the size and boundaries of the leaking area.
This level of detail influences treatment decisions, including the choice of medication and how often injections may be needed. When a patient does not respond to an initial treatment plan, fluorescein angiography can also help uncover whether a different type of CNV or a separate condition is contributing to ongoing vision changes.
OCT angiography (OCTA) is a newer noninvasive technique that can visualize blood flow without dye injection. While it offers real advantages, it has recognized limitations, particularly when imaging blood flow beneath areas where the retinal pigment epithelium (the supportive cell layer under the retina) has separated from its base.
In these complex situations, fluorescein angiography can provide the complete diagnostic picture that OCTA alone cannot. Both technologies serve important roles, and experienced retina specialists use them in a way that gives each patient the most accurate information possible.
Who Should Have This Test?
Not every patient with AMD will need fluorescein angiography. The test is ordered based on your specific symptoms, risk level, and how your condition is responding to any current care.
Fluorescein angiography is indicated for any AMD patient who develops vision loss, metamorphopsia (the perception that straight lines appear wavy or distorted), or a scotoma (a blind or dark spot in the central visual field) when CNV is suspected. These symptoms may signal the onset of wet AMD and require prompt evaluation.
Clinical signs that raise concern include elevation of the retinal pigment epithelium, bleeding beneath the retina, and exudate (fatty deposits left by leaking vessels). Even patients who have not yet noticed new symptoms may show these changes during a careful examination.
AMD is the leading cause of significant vision loss in people over age 50 in developed countries. Risk factors for progression include advancing age, a history of smoking, a family history of AMD, and certain genetic factors.
For patients who show signs of moving from dry to wet AMD, a retina specialist may recommend fluorescein angiography to get a clear picture of what is happening before symptoms become severe. Early detection gives treatment the best opportunity to preserve vision.
When a patient receiving anti-VEGF (anti-vascular endothelial growth factor) injections, the standard treatment for wet AMD, does not show expected improvement, fluorescein angiography can help identify why. The test may reveal persistent or recurrent CNV, a different subtype of CNV than originally identified, or an additional condition contributing to the vision changes.
This information allows the treating retina specialist to adjust the plan and ensure the most appropriate therapy is being used for your specific situation.
What to Expect During the Procedure
Most patients find fluorescein angiography to be straightforward and well-tolerated. Knowing what to expect can help you feel prepared and comfortable from start to finish.
Your care team will review your medical history and ask about any known allergies, especially to dyes. Dilating eye drops will be placed in your eyes to widen the pupils, which allows a clearer view of the retina. Dilation typically takes about 20 to 30 minutes to take full effect.
- Bring sunglasses, as your eyes will be sensitive to light for several hours after the procedure
- Arrange for someone to drive you home, since dilation temporarily affects your near vision and light sensitivity
- Let your care team know about any previous reactions to fluorescein dye
A technician will place a small needle into a vein in your arm or hand, similar to a standard blood draw. The fluorescein dye is injected through this needle, and within seconds it reaches the blood vessels in your eyes. The camera takes a rapid series of photographs as the dye flows through, and you may be asked to look in different directions to allow all areas of the retina to be captured.
Most patients feel a brief warm sensation throughout the body as the dye is injected. The imaging itself is not painful. The full imaging process generally takes about 10 minutes, with additional photographs sometimes taken at the 5 to 10 minute mark to capture late-phase images.
Following the test, your skin may appear slightly yellow for a few hours, and your urine will turn bright orange or yellow for one to two days. Both of these changes are completely normal and reflect your body clearing the dye. Drinking extra water during this time helps flush the fluorescein from your system more quickly.
Most patients return to their regular activities the same day. Your retina specialist will review the images and discuss the findings with you, often at the same visit or at a scheduled follow-up appointment.
Fluorescein angiography is considered a safe procedure for the great majority of patients. The most common side effect is brief, mild nausea at the time of injection, which typically passes within minutes.
Allergic reactions to the dye are rare, but they can range from mild hives to more serious responses. Your medical team will be prepared with appropriate equipment as a precaution. If you have a known history of allergic reactions to fluorescein dye, be sure to share this with your retina specialist before the test is scheduled.
How This Test Connects to AMD Treatment
Fluorescein angiography does not just diagnose AMD. It provides the foundation for treatment decisions and helps ensure your care plan stays on the right track over time.
Before starting treatment for wet AMD, a retina specialist uses fluorescein angiography to create a baseline record of the disease. This initial imaging documents the location, size, and type of CNV present and serves as a reference point for measuring whether treatment is working.
Currently approved anti-VEGF medications for wet AMD include aflibercept (Eylea), ranibizumab (Lucentis), faricimab (Vabysmo), and brolucizumab (Beovu). Bevacizumab (Avastin), approved by the FDA for cancer treatment, is also widely used off-label for wet AMD. Angiographic findings may help guide which medication is best suited for a given patient.
For routine follow-up visits, OCT is often the preferred monitoring tool because it is noninvasive and quick. However, when OCT findings are unclear or when a patient is not improving as expected, fluorescein angiography provides the additional detail needed to understand what is happening.
The test can reveal the source and extent of persistent leakage, identify new areas of CNV, or confirm that treatment has successfully closed the abnormal vessels. Both OCT and fluorescein angiography are recognized as valid tools for evaluating AMD treatment response.
Fluorescein angiography is not needed at every appointment. For many patients with wet AMD, the test is performed at the time of initial diagnosis and repeated only when there is a specific clinical reason to do so, such as a sudden change in vision or a lack of response to ongoing treatment.
As imaging technology continues to advance, fluorescein angiography remains a foundational tool. Its ability to directly visualize dye leakage from abnormal blood vessels gives it a unique diagnostic role that OCT and OCTA have not fully replaced.
When to Seek Urgent Care
AMD can change, and knowing which symptoms require immediate attention versus scheduled follow-up can make a real difference in protecting your vision.
Some symptoms require immediate evaluation, not a scheduled appointment. If you experience any of the following, contact a retina specialist or go to an emergency eye care provider right away.
- Sudden loss of vision in one eye
- A curtain, shadow, or dark veil over part of your vision
- A sudden increase in floaters or flashes of light
These symptoms may indicate a serious and rapidly progressing change that needs same-day assessment.
If you have been diagnosed with dry AMD and notice new or worsening distortion of straight lines, a dark or missing area in your central vision, or increasing difficulty reading even with your glasses, contact a retina specialist promptly. Metamorphopsia, the perception that straight lines look wavy or bent, may indicate the early onset of choroidal neovascularization.
Early detection of wet AMD through timely fluorescein angiography and other diagnostic testing gives anti-VEGF treatment the best chance of preserving your remaining vision.
If you are over age 50 and have known risk factors for AMD, regular comprehensive eye examinations are important for catching early changes before they affect your vision. Patients already diagnosed with AMD in one eye are at higher risk for developing the condition in the other eye and benefit from more frequent monitoring.
An Amsler grid, a simple printed chart with a grid of straight lines, can be used at home to monitor your central vision between appointments. Any new distortion, waviness, or missing areas on the grid should be reported to your care team without delay.
Frequently Asked Questions
These answers address some of the more specific questions patients often have when fluorescein angiography is recommended as part of their AMD care.
Fluorescein dye has a long, well-established safety record and is not the same as iodine-based contrast used in CT scans or MRI procedures. Mild side effects such as temporary skin yellowing and nausea are the most common reactions. Serious allergic reactions are rare. If you have had a previous reaction to fluorescein dye or have significant kidney concerns, be sure to discuss this with your retina specialist before the test, so any necessary precautions can be taken.
Yes, in many situations both tests together provide information that neither can offer alone. OCT excels at measuring retinal thickness and detecting fluid in the retinal layers, while fluorescein angiography reveals whether blood vessels are actively leaking and where. When both tests are ordered, it is because your retina specialist needs a complete picture of your condition to make the most accurate treatment decisions on your behalf.
Most patients receiving anti-VEGF injections do not need fluorescein angiography at every visit. OCT is generally sufficient for routine monitoring between injection appointments. Fluorescein angiography is typically repeated when there is a new symptom, an unexpected finding on OCT, a lack of response to treatment, or a concern that the disease has changed in a way that requires reclassification. Your retina specialist will determine the right timing for your individual case.
The safety of fluorescein dye during pregnancy has not been fully established. If you are pregnant or think you may be, let your retina specialist know before the test is scheduled. In many cases, OCT can be used as an alternative for monitoring purposes during pregnancy, and the decision to proceed with fluorescein angiography will depend on how urgently the diagnostic information is needed versus the potential risks involved.
Patients with dry AMD may not need fluorescein angiography unless signs of conversion to wet AMD appear. However, dry AMD can progress over time and, in some patients, transitions to the wet form. If you develop new symptoms such as distorted vision or a new dark spot in your central vision, your retina specialist may order fluorescein angiography at that point to determine whether CNV has developed and to guide next steps. Routine monitoring with OCT and regular eye exams remains important even with a dry AMD diagnosis.
An abnormal result typically means that leaking or abnormal blood vessels have been identified. Depending on the type, location, and extent of CNV found, your retina specialist will discuss treatment options with you. For wet AMD, anti-VEGF injections are the primary treatment and are typically started as promptly as possible after diagnosis to minimize further vision loss. If your case requires more complex surgical or interventional retinal care, your specialist can refer you to an appropriate provider who focuses on those services.
Schedule Your Eye Care Evaluation
At NewView Eye Center, our team is committed to providing personalized, thorough care for patients with AMD and other retinal conditions throughout Northern Virginia. We use advanced diagnostic imaging, including fluorescein angiography, to ensure every patient receives an accurate diagnosis and a care plan tailored to their specific needs. If you are experiencing changes in your central vision or have been told you may be at risk for AMD, we encourage you to schedule an evaluation with our team so we can help you protect and preserve your sight.
What our Patients Says
Explore More
Find more information about our doctors, services, and technology that keep your eyes healthy and your vision at its best.
Uveitis: Understanding Eye Inflammation and Protecting Your Vision
Retinal Disease: What Every Patient Needs to Know
Laser Floater Removal: Relief for Bothersome Eye Floaters
Vitreous Hemorrhage: Causes, Treatment, and Recovery
Vitrectomy Surgery: What Patients Need to Know
Retinopathy of Prematurity: A Guide for Parents